

ANTIGENICS INC /DE/  
Form 8-K  
March 20, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

March 15, 2006

Date of Report (Date of earliest event reported)

---

**ANTIGENICS INC.**

(Exact name of registrant as specified in its charter)

---

**DELAWARE**  
(State or other jurisdiction

of incorporation)

**000-29089**  
(Commission

File Number)

**06-1562417**  
(IRS Employer

Identification No.)

**630 Fifth Avenue, Suite 2100**

**New York, NY 10111**  
(Address of principal executive offices)

**212-994-8200**

(Registrant's telephone number, including area code)

**10111**  
(Zip Code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement**

On March 15, 2006, the Compensation Committee of the Board of Directors of Antigenics Inc. (the Company) awarded the following cash bonuses to the Company's named executives:

Peter Thornton, Sr. Vice-President and Chief Financial Officer	\$ 91,200
Renu Gupta, Sr. Vice-President, Development	\$ 97,500
Roman Chicz, Sr. Vice-President, Research & Preclinical development	\$ 79,500
Bruce Leicher, Vice-President, General Counsel	\$ 6,840

All bonus awards are recommended based on achievement of goals and benchmark data.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: March 20, 2006

By: /s/ Garo H. Armen  
Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer